-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, LX4wu/B8ijYaIFv6ATV9j0CRULW5yFeq4aIzb17GKFag8KFYWkvRQGJKJOE0w2CL ZwNnGPBeZy/+RqJDHTMfnA== 0000891618-99-002291.txt : 20040503 0000891618-99-002291.hdr.sgml : 20040503 19990517115100 ACCESSION NUMBER: 0000891618-99-002291 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 19990331 FILED AS OF DATE: 19990517 DATE AS OF CHANGE: 20020325 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HEALTHEON CORP CENTRAL INDEX KEY: 0001009575 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMPUTER PROCESSING & DATA PREPARATION [7374] IRS NUMBER: 943236644 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-24975 FILM NUMBER: 99625836 BUSINESS ADDRESS: STREET 1: RIVER DRIVE CENTER 2 STREET 2: 669 RIVER DR CITY: ELMWOOD PARK STATE: NJ ZIP: 07407 BUSINESS PHONE: 4088765000 MAIL ADDRESS: STREET 1: RIVER DRIVE CENTER 2 STREET 2: 669 RIVER DR CITY: ELMWOOD PARK STATE: NJ ZIP: 07407 FORMER COMPANY: FORMER CONFORMED NAME: HEALTHEON CORP DATE OF NAME CHANGE: 19980729 FORMER COMPANY: FORMER CONFORMED NAME: HEALTHSCAPE CORP DATE OF NAME CHANGE: 19970404 10-Q 1 FORM 10-Q FOR PERIOD ENDED MARCH 31, 1999 1 ================================================================================ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 -------------------------- FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 1999 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to __________ Commission file number 333-70553 HEALTHEON CORPORATION (Exact name of Registrant as specified in its charter) DELAWARE 94-3236644 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification Number) 4600 PATRICK HENRY DRIVE SANTA CLARA, CALIFORNIA 95054 (Address of principal executive offices) (408) 876-5000 (Registrant's telephone number, including area code) -------------------------- Check whether the registrant: (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES [ ] NO [X] As of April 30, 1999, there were 70,976,757 shares of the Registrant's Common Stock outstanding. ================================================================================ 2 HEALTHEON CORPORATION QUARTERLY REPORT ON FORM 10-Q FOR THE PERIOD ENDED MARCH 31, 1999 INDEX
PAGE PART I FINANCIAL INFORMATION NUMBER ITEM 1. Financial Statements: Condensed Consolidated Balance Sheets as of March 31, 1999 and December 31, 1998....................................... 3 Condensed Consolidated Statements of Operations for the three months ended March 31, 1999 and 1998........................ 4 Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 1999 and 1998........................ 5 Notes to Condensed Consolidated Financial Statements........... 6 ITEM 2. Management's Discussion and Analysis of Financial Condition and Results of Operations................................... 8 ITEM 3. Quantitative and Qualitative Disclosures About Market Risk .... 19 PART II OTHER INFORMATION ITEM 2. Changes in Securities and Use of Proceeds...................... 20 ITEM 6. Exhibits and Reports on Form 8-K............................... 20 Signatures..................................................... 21
2 3 PART I: FINANCIAL INFORMATION ITEM 1. FINANCIAL STATEMENTS HEALTHEON CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands)
MARCH 31, DECEMBER 31, 1999 1998 ---------- ---------- (unaudited) (1) ASSETS Current assets: Cash and cash equivalents .......................... $ 38,389 $ 19,389 Short-term investments ............................. 24,786 17,428 Accounts receivable, net ........................... 10,424 7,954 Other current assets ............................... 1,561 706 ---------- ---------- Total current assets ............................ 75,160 45,477 Property and equipment, net ........................... 17,410 12,285 Intangible assets, net ................................ 24,828 19,868 Other assets .......................................... 3,657 2,310 ---------- ---------- $ 121,055 $ 79,940 ========== ========== LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Notes payable ...................................... $ 1,054 $ 1,213 Accounts payable ................................... 4,017 5,178 Accrued liabilities ................................ 11,110 6,983 Current portion of capital lease obligations ....... 2,393 2,295 Deferred revenue ................................... 3,597 1,874 ---------- ---------- Total current liabilities ....................... 22,171 17,543 Capital lease obligations, net of current portion ..... 3,153 2,984 Stockholders' equity: Convertible preferred stock ........................ -- 46,101 Common stock ....................................... 7 5 Additional paid-in capital ......................... 228,833 123,670 Deferred stock compensation ........................ (11,112) (6,935) Accumulated deficit ................................ (121,997) (103,428) ---------- ---------- Total stockholders' equity ...................... 95,731 59,413 ---------- ---------- $ 121,055 $ 79,940 ========== ==========
(1) Derived from audited financial statements as of December 31, 1998. See notes to condensed consolidated financial statements. 3 4 HEALTHEON CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except per share data; unaudited)
THREE MONTHS ENDED MARCH 31, ----------------------- 1999 1998 -------- -------- Revenue(1) ............................................ $ 17,555 $ 9,754 Operating costs and expenses: Cost of revenue(1) .................................. 16,860 7,948 Development and engineering ......................... 7,341 3,919 Sales, general and administrative ................... 9,022 4,966 Amortization of intangible assets ................... 3,459 1,949 -------- -------- Total operating costs and expenses ................ 36,682 18,782 -------- -------- Loss from operations .................................. (19,127) (9,028) Interest income ....................................... 697 358 Interest expense ...................................... (139) (116) Dividends on ActaMed's convertible redeemable preferred stock .......................... -- (890) -------- -------- Net loss .............................................. $(18,569) $ (9,676) ======== ======== Basic and diluted net loss per common share ........... $ (0.30) $ (1.19) ======== ======== Weighted average shares outstanding used in computing basic and diluted net loss per common share ........................................ 62,665 8,099 ======== ========
(1) Includes revenue to related parties of $9,521 and $4,656 and cost of revenue of $8,643 and $2,860 for the three months ended March 31, 1999 and 1998. See note 3. See notes to condensed consolidated financial statements. 4 5 HEALTHEON CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands, unaudited)
THREE MONTHS ENDED MARCH 31, ----------------------- 1999 1998 -------- -------- CASH FLOWS FROM OPERATING ACTIVITIES: Net loss ..................................................... $(18,569) $ (9,676) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization .............................. 8,030 4,021 Dividends on ActaMed's convertible redeemable preferred stock ......................................... -- 890 Changes in operating assets and liabilities: Accounts receivable ...................................... (2,470) (529) Other assets ............................................. (3,069) (365) Accounts payable ......................................... (1,161) 1,703 Accrued liabilities ...................................... 4,175 359 Deferred revenue ......................................... 1,723 624 -------- -------- Net cash used in operating activities .................. (11,341) (2,973) -------- -------- CASH FLOWS FROM INVESTING ACTIVITIES: Purchases of short-term investments .......................... (15,148) (3,083) Maturities of short-term investments ......................... 7,790 7,059 Decrease in restricted cash .................................. 867 -- Purchases of property and equipment .......................... (4,048) (2,021) -------- -------- Net cash provided by (used in) investing activities ............................................. (10,539) 1,955 -------- -------- CASH FLOWS FROM FINANCING ACTIVITIES: Payments of notes payable .................................... (159) -- Proceeds from issuance of common stock, net of issuance costs ......................................... 41,755 26 Payments on note receivable from officer ..................... -- 168 Principal payments of capital lease obligations .............. (716) (322) -------- -------- Net cash provided by (used in) financing activities ............................................. 40,880 (128) -------- -------- Net increase (decrease) in cash and cash equivalents ............ 19,000 (1,146) Cash and cash equivalents at beginning of period ................ 19,389 16,504 -------- -------- Cash and cash equivalents at end of period ...................... $ 38,389 $ 15,358 ======== ======== SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: Interest paid ................................................ $ 139 $ 116 ======== ======== SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES: Equipment acquired under capital leases ...................... $ 983 $ 277 ======== ======== Issuance of common stock for assets purchased ................ $ 11,000 $ 2,800 ======== ======== Deferred compensation related to options granted ............. $ 6,261 $ 1,353 ======== ======== Conversion of convertible preferred stock to common stock ........................................................ $ 46,101 $ -- ======== ========
See notes to condensed consolidated financial statements. 5 6 HEALTHEON CORPORATION NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The unaudited condensed consolidated financial statements have been prepared by Healtheon's management and reflect all adjustments that, in the opinion of management, are necessary for a fair presentation of the interim periods presented. The results of operations for the three months ended March 31, 1999 are not necessarily indicative of the results to be expected for any subsequent quarter or for the entire year ending December 31, 1999. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted under the Securities and Exchange Commission's rules and regulations. A condensed consolidated statement of comprehensive loss has not been presented because the components of comprehensive loss are not material. Healtheon derives its revenue from a single operating segment, healthcare transaction and information services delivered over the Internet, private intranets or other networks and from development and consulting contracts related to these services. In addition, we manage the information technology operations of some of our customers. Healtheon's operations outside of the United States are not significant, and to date has derived all of its revenue from within the United States. Assets located outside of the United States are insignificant at March 31, 1999. These unaudited condensed consolidated financial statements and notes included herein should be read in conjunction with Healtheon's audited consolidated financial statements and notes for the year ended December 31, 1998 which were included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission. Net Loss per Common Share The following table presents the calculation of basic and diluted net loss per common share (in thousands, except per share data):
THREE MONTHS ENDED MARCH 31, ----------------------- 1999 1998 -------- -------- Net loss .............................................................. $(18,569) $ (9,676) ======== ======== Basic and diluted: Weighted-average shares of common stock outstanding ................. 63,789 9,498 Less: Weighted-average common shares subject to repurchase .......... (1,124) (1,399) -------- -------- Weighted-average shares used in computing basic and diluted net loss per common share ............................................... 62,665 8,099 ======== ======== Basic and diluted net loss per common share ........................... $ (0.30) $ (1.19) ======== ========
We have excluded all convertible redeemable preferred stock, convertible preferred stock, warrants, outstanding stock options and shares subject to repurchase by Healtheon from the calculation of diluted net loss per common share because all such securities are anti-dilutive for the periods presented. The total number of shares excluded from the calculation of diluted loss per shares was 18,208,030 at March 31, 1999 and 52,570,914 at March 31, 1998. 2. SERVICES AGREEMENT WITH SMITHKLINE BEECHAM CLINICAL LABORATORIES, INC. In January 1999, Healtheon and SmithKline Beecham Clinical Laboratories, Inc., or SmithKline Labs, entered into a services agreement under which Healtheon will provide certain electronic laboratory results delivery services to approximately 20,000 provider sites, in addition to the sites currently served through the SCAN service. In addition, in January 1999, the two companies completed an asset purchase agreement under which Healtheon purchased certain assets currently used by SmithKline Labs to provide these laboratory results delivery services in exchange for $2,000,000 in cash and 1,833,333 shares of Healtheon's common stock with a value of $11,000,000. 6 7 3. RELATED PARTY TRANSACTIONS Revenue from services to related parties consists of services revenue attributable to two customers who are significant stockholders of Healtheon. Receivables due from these related parties included in accounts receivable on the condensed consolidated balance sheets were $4,905,000 at March 31, 1999 and $3,360,000 at December 31, 1998. 4. STOCKHOLDERS' EQUITY From January 1, 1999 through February 10, 1999, the date of our initial public offering, Healtheon granted to employees options to purchase common stock equal to a total of 4,107,625 shares with exercise prices ranging from $3.55 to $5.85 per share. We have recorded deferred stock compensation of $6,261,000 related to these grants. On February 10, 1999, Healtheon completed its initial public offering. We sold 5,750,000 shares of common stock to the public and realized net proceeds of approximately $41,398,000. 5. SUBSEQUENT EVENT On April 21, 1999 we announced that we have entered into an agreement to acquire MedE America Corporation ("MedE"), a leading provider of healthcare transaction solutions for pharmacies, hospitals, physicians, dentists, payers and pharmacy benefits managers (PBMs). Under the terms of the agreement, Healtheon will exchange 0.6593 shares of common stock, subject to adjustment if the price of the Healtheon stock is greater than $63.99 or less than $38.39, for each share of MedE stock. Based on Healtheon's closing price on April 20, 1999, the transaction is preliminarily valued at approximately $460 million. The acquisition, which is expected to be accounted for using the purchase method of accounting, is anticipated to be completed in the third quarter of 1999. The transaction is subject to customary closing conditions, including approval by MedE stockholders, and is subject to regulatory review. 7 8 ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS FORWARD-LOOKING STATEMENTS Except for historical information, this Report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve risks and uncertainties, including, among other things, statements regarding our anticipated costs and expenses, revenue mix, product and service development, relationships with strategic partners and plans for addressing Year 2000 issues. These forward-looking statements include, among others, those statements including the words "expects," "anticipates," "intends," "believes" and similar language. Our actual results may differ materially from those projected in the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, those discussed in the section "--Factors That May Affect Future Results of Operations." You should carefully review the risks described in other documents we file from time to time with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 1998. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this Quarterly Report on Form 10-Q. We undertake no obligation to publicly release any revisions to the forward-looking statements or reflect events or circumstances after the date of this document. The following discussion also should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 1998 included in our Annual Report on Form 10-K as filed with the Securities and Exchange Commission. OVERVIEW Healtheon is pioneering the use of the Internet to simplify workflows, decrease costs and improve the quality of patient care throughout the healthcare industry. Healtheon's Virtual Healthcare Network, or VHN, solution enables the secure exchange of information among a wide array of disparate healthcare information systems and provides a framework for a broad range of healthcare transactions. Healtheon's revenue to date has been derived primarily from proprietary non-Internet network-based services and from management and operation of customers' information technology, or IT, infrastructure. Our revenue and income potential is unproven and our business model is still emerging. Our historical financial information is of limited value in projecting our future operating results because of our limited operating history as a combined organization and the emerging nature of our markets. We have lost money since we began operations and, as of March 31, 1999, we had an accumulated deficit of $122.0 million. We plan to invest heavily in acquisitions, infrastructure development, applications development and sales and marketing. As a result, we expect that we will continue to lose money through 1999 and we may never achieve or sustain profitability. RESULTS OF OPERATIONS Revenue We have developed strategic relationships with healthcare industry leaders, including UnitedHealth Group, SmithKline Labs, Brown & Toland and Beech Street. These four companies each accounted for over 10% of our total revenue in the first quarter of 1999. We expect that a small number of customers will continue to account for a substantial portion of our revenue for the foreseeable future. The loss of one or more of our significant customers, or a decline in the volume of business generated by these customers, could have a material adverse effect on our business, financial condition and results of operations. Healtheon earns revenue from services which include providing access to our network-based services, including fixed fee and transaction based services, and performing development and consulting services, and from licensing software. Services revenue also includes revenue from the management and operation of customers' IT infrastructure. Customers may purchase some or all of Healtheon's applications and services and 8 9 the customer relationship may evolve from utilizing development and consulting services to utilizing transaction and subscription-based services. Healtheon earns network-based services revenue from fixed fee subscription arrangements, which revenue is recognized ratably over the term of the applicable agreement, and from arrangements that are priced on a per-transaction or per-user basis, which revenue is recognized as the services are performed. Revenue from development projects is recognized on a percentage-of-completion basis or as the services are performed, depending on the terms of the contract. Revenue from consulting services and revenue from the management and operation of customers' IT infrastructure is recognized as the services are performed. Cash received in excess of revenue recognized relating to these services has been recorded as deferred revenue. At March 31, 1999, we had deferred revenue of approximately $3.6 million. Total revenue increased to $17.6 million in the first quarter of 1999 from $9.8 million in the first quarter of 1998. Revenue from the Service Agreements with UnitedHealth and SmithKline Labs increased to $9.5 million from the first quarter of 1999 from $4.7 million in the first quarter of 1998. Increased transaction based services under the UnitedHealth Group Agreement, and additional revenue from the January 1999 Services Agreement with SmithKline Labs, which was phased in during the first quarter of 1999 contributed to the significant increases in revenue. In addition, our revenue increased due to contracts with new customers and increased revenue from existing customers, Brown & Toland and Beech Street. We recognized revenue for IT services of $4.9 million in the first quarter of 1999 and $3.8 million in the first quarter of 1998. In addition, we recognized revenue related to IT development services of $0.5 million in the 1999 period and $0.8 million in the 1998 period. The UnitedHealth Group Agreement has a five-year term. However, the agreement provides that two years after the date of the agreement, which was signed on April 4, 1996, the parties will agree on new prices that are competitive with the marketplace. Healtheon and UnitedHealth Group are negotiating the new prices and we anticipate that the new prices will reduce the rates paid by UnitedHealth Group, on a prospective basis. The Services Agreements with SmithKline Labs also each have a five-year term. However, the December 1997 Services Agreement provides that the parties will negotiate new rates as of January 1, 2001 and every two years thereafter. Under the terms of the Services Agreement, the renegotiated rates must be competitive with the marketplace and must be no higher than the lowest fees charged by Healtheon to similar customers. Cost of Revenue Cost of revenue consists of costs related to services Healtheon provides to customers and costs associated with the operation and maintenance of our networks. These costs include salaries and related expenses for consulting and development personnel, network operations personnel and customer support personnel; telecommunication costs; depreciation and maintenance of network equipment; amortization of certain intangible assets; a portion of facilities expenses; and leased personnel and facilities costs. Given Healtheon's limited operating history, changes in revenue mix, limited history of Internet-based network services, recent investments in personnel, amortization of infrastructure investments and evolving business model, we believe that analysis of historical cost of revenue as a percentage of revenue is not meaningful. We anticipate that our total cost of revenue will increase in absolute dollars in the future. Cost of revenue was $16.9 million in the first quarter of 1999 and $7.9 million in the first quarter of 1998. These increases resulted mainly from higher personnel and network operation costs required to support our increased service revenues. Development and Engineering Development and engineering expense, which excludes development expenses that are included in cost of revenue, consists primarily of salaries and related expenses associated with the development of applications and services. Expenses include compensation paid to engineering personnel, fees to outside contractors and consultants, a portion of facilities expenses and the depreciation and maintenance of capital equipment used in the development process. We believe our success is partially dependent upon our ability to introduce new applications in several healthcare markets in a relatively short period of time. Accordingly, Healtheon intends to continue recruiting and hiring experienced engineering personnel and to continue making other investments 9 10 in development and engineering. We expect that development and engineering expenses will continue to increase in absolute dollars. Currently, all development and engineering expenses are expensed as incurred. Development and engineering expense was $7.3 million in the first quarter of 1999 and $3.9 million in the first quarter of 1998. The increase was the result of a significant increase in the number of engineers engaged in the development of our applications and services. Sales, General and Administrative Sales, general and administrative expense consists primarily of salaries and related expenses for sales, account management, marketing, administrative, finance, legal, human resources and executive personnel; commissions; costs and expenses for marketing programs and trade shows; fees for professional services; and costs of accounting and internal control systems to support our operations. We anticipate that sales, general and administrative expense will continue to increase in absolute dollars as we add sales, marketing and administrative personnel, increase our marketing and promotional activities and incur costs related to being a public company, such as directors' and officers' liability insurance premiums and professional fees. Sales, general and administrative expense increased to $9.0 million in the first quarter of 1999 from $5.0 million in the first quarter of 1998. The amortization of deferred stock compensation accounted for $1.6 million of the increase. The remainder of the increase resulted from salaries and related costs of added sales personnel and executive management. Deferred stock compensation represents the difference between the purchase or exercise price of certain restricted stock and stock option grants and the deemed fair value of Healtheon's common stock at the time of those grants. Healtheon recorded deferred stock compensation of $6.3 million in the first quarter of 1999, $8.2 million in the full year of 1998 and $2.7 million in the full year of 1997. The deferred stock compensation balance at March 31, 1999 was $11.1 million. The deferred stock compensation balance is being amortized based on a graded vesting method over the vesting period, generally four years, of the option or restricted stock grants. Amortization is estimated to total $7.8 million in 1999, $3.5 million in 2000, $1.5 million in 2001 and $.4 million for 2002. Amortization of Intangible Assets Amortization of intangible assets was $4.2 million in the first quarter of 1999 and $1.9 million in the first quarter of 1998. All of the intangible assets are being amortized over expected lives of three to five years. The increase is due primarily to the January 1999 Services Agreement with SmithKline Labs and the acquisition of Metis LLC in August 1998. Amortization charges are estimated to be $11.8 million in 1999, $10.0 million in 2000, $3.4 million in 2001, $1.8 million in both 2002 and 2003 and $.2 million in 2004 assuming no impairment of the remaining unamortized intangible asset balances and no additional acquisitions of intangible assets. Interest Income and Expense Interest income has been derived primarily from cash investments. Interest expense results primarily from our borrowings and from capitalized lease obligations for equipment purchases. Net interest income was $0.6 million in the first quarter of 1999 and $0.2 million in the first quarter of 1998. The increase for the 1999 period was due to higher average cash balances resulting from the proceeds of our $46.1 million preferred stock financing in October 1998 and the net proceeds of $41.4 million from our initial public offering in February 1999. Dividends on ActaMed's Convertible Redeemable Preferred Stock Healtheon acquired ActaMed in a transaction accounted for as a pooling-of-interests in May 1998. Because dividends on ActaMed's convertible redeemable preferred stock were cumulative whether declared or not, ActaMed accrued the dividends on a quarterly basis. Dividends of $.9 million were charged against income in the consolidated statements of operations in the first quarter of 1998. None of the dividends were paid, and, in conjunction with approving the acquisition of ActaMed by Healtheon, ActaMed's preferred stockholders waived their right to receive the dividends, which totaled $7.5 million at the time of the acquisition. The ActaMed preferred stockholders received an aggregate of 17.3 million shares of Healtheon common stock in exchange for their ActaMed convertible redeemable preferred stock. 10 11 FACTORS THAT MAY AFFECT FUTURE RESULTS OF OPERATIONS Our quarterly operating results may vary. Fluctuations in our quarterly results could affect the market price of our common stock in a manner unrelated to our long-term operating performance. We expect that our quarterly revenue and operating results may fluctuate as a result of a number of factors, including: - changes in our strategic relationships; - future acquisitions; - our entry into new healthcare markets; - new customers; - new application and service offerings; - software defects, delays in development and other quality factors; - customer demand for our applications and services; - our ability to meet project milestones or customer expectations; - our mix of consulting and transaction fee revenue; - variability in demand of Internet-based healthcare solutions; - changes within the healthcare industry; and - seasonality of demand. We expect to increase activities and spending in substantially all of our operational areas. We base our expense levels in part upon our expectations concerning future revenue and these expense levels are relatively fixed in the short-term. If we have lower revenue, we may not be able to reduce our spending in the short-term in response. Any shortfall in revenue would have a direct impact on our results of operations. For these and other reasons, we may not meet the earnings estimates of securities analysts or investors and our stock price could suffer. The healthcare industry may not accept our solutions. To be successful, we must attract a significant number of customers throughout the healthcare industry. To date, the healthcare industry has been resistant to adopting new information technology solutions. Electronic information exchange and transaction processing by the healthcare industry is still developing. We believe that complexities in the nature of the healthcare transactions that must be processed have hindered the development and acceptance of information technology solutions by the industry. Conversion from traditional methods to electronic information exchange may not occur as rapidly as we expect it will. Even if the conversion does occur as rapidly as we expect, healthcare industry participants may use applications and services offered by others. We believe that we must gain significant market share with our applications and services before our competitors introduce alternative products, applications or services with features similar to our current or proposed offerings. Our business plan is based on our belief that the value and market appeal of our solution will grow as the number of participants and the scope of the transaction services available on our platform increase. We may not achieve the critical mass of users we believe is necessary to become successful. In addition, we expect to generate a significant portion of our revenue from subscription and transaction-based fees. Consequently, any significant shortfall in the number of users or transactions occurring over our platform would adversely affect our financial results. We rely on strategic relationships to generate revenue. To be successful, we must establish and maintain strategic relationships with leaders in a number of healthcare industry segments. This is critical to our success because we believe that these relationships will enable us to: - extend the reach of our applications and services to the various participants in the healthcare industry; - obtain specialized healthcare expertise; - develop and deploy new applications; 11 12 - further enhance the Healtheon brand; and - generate revenue. Entering into strategic relationships is complicated because some of our current and future partners may decide to compete with us. In addition, we may not be able to establish relationships with key participants in the healthcare industry if we have established relationships with competitors of these key participants. Consequently, it is important that we are perceived as independent of any particular customer or partner. Moreover, many potential partners may resist working with us until our applications and services have been successfully introduced and have achieved market acceptance. As we establish strategic relationships, we will depend on our partners' ability to generate increased acceptance and use of our platform, applications and services. To date, we have established only a limited number of strategic relationships and these relationships are in the early stages of development. We have limited experience in establishing and maintaining strategic relationships with healthcare industry participants. If we lose any of these strategic relationships or fail to establish additional relationships, or if our strategic partners fail to actively pursue additional business relationships and partnerships, we would not be able to execute our business plans and our business would suffer significantly. On February 9, 1999, SmithKline Beecham announced that it has agreed to sell SmithKline Labs to Quest Diagnostics, Incorporated. SmithKline Labs has been one of our strategic partners since December 1997, and our relationship with them has been beneficial. Our agreements with SmithKline Labs will remain in effect as a result of the acquisition. However, we will need to work with a new business partner, which involves risks such as different customer requirements and working relationships. At this time, we are not aware of Quest's intentions regarding our relationship with SmithKline Labs. Our business could be adversely affected if Quest does not pursue the relationship to the same extent as SmithKline Labs. In addition, our ability to take advantage of our relationship with SmithKline Labs may be impaired because the attention of management of the combining companies may be diverted during and after the acquisition. We may not experience increased use of our platform, applications and services even if we establish and maintain these strategic relationships. Our business will suffer if we do not expand our suite of applications. Our business will suffer if we do not expand the breadth of our applications quickly. We currently offer a limited number of applications on our platform and our future success depends on quickly introducing new applications in several healthcare segments. We do not have the internal resources and specialized healthcare expertise to develop all these applications independently. Consequently, we must rely on a combination of internal development, strategic relationships, licensing and acquisitions to develop these applications. Each of our applications, regardless of how it was developed, must be integrated and customized to operate with existing customer legacy computer systems and our platform. Developing, integrating and customizing these applications will be expensive and time consuming. Even if we are successful, these applications may never achieve market acceptance, which could also cause our business to suffer. We must acquire technologies and companies to increase our customer base. We expect to continue to acquire technologies and other healthcare technology companies to increase the number and variety of applications on our platform and to increase our customer base. For example, in May 1998 we acquired ActaMed, in August 1998 we acquired substantially all the assets of Metis, LLC, and in April 1999 we announced that we have entered into an agreement to acquire MedE America Corporation, or MedE. See Note 5 of "Notes to Condensed Consolidated Financial Statements." To be successful, we will need to identify applications, technologies and businesses that are complementary to ours, integrate disparate technologies and corporate cultures and manage a geographically dispersed company. Acquisitions could divert our attention from other business concerns and expose us to unforeseen liabilities or risks associated with entering new markets. Finally, we may lose key employees while integrating these new companies. Integrating newly acquired organizations and technologies into our company could be expensive, time consuming and may strain our resources. In addition, we may lose our current customers if any acquired companies have relationships with competitors of our customers. Consequently, we may not be successful in integrating acquired businesses or technologies and may not achieve anticipated revenue and cost benefits. The healthcare industry is consolidating and we expect that we will face intensified competition for acquisitions, especially from larger, better-funded organizations. If we fail to execute our acquisition strategy successfully for any reason, our business will suffer significantly. 12 13 We intend to pay for some of our acquisitions by issuing additional common stock and this could dilute our stockholders. We may also use cash to buy companies or technologies in the future. If we do use cash, we may need to incur debt to pay for these acquisitions. Acquisition financing may not be available on favorable terms or at all. In addition, we may be required to amortize significant amounts of goodwill and other intangible assets in connection with future acquisitions, which would materially increase our operating expenses. We must manage our growth. We have rapidly and significantly expanded our operations and expect to continue to do so. This growth has placed, and is expected to continue to place, a significant strain on our managerial, operational, financial and other resources. As of March 31, 1999, we have grown our headcount significantly over the prior year. A large portion of this increase resulted from our acquisitions of ActaMed in May 1998 and Metis, LLC in August 1998, which increased our payroll by 230 employees. We expect to continue to hire a significant number of new employees to support our business. In addition, the proposed acquisition of MedE will increase our headcount by approximately 450 employees. Our current information systems, procedures and controls may not continue to support our operations and may hinder our ability to exploit the market for healthcare applications and services. We are in the process of evaluating our accounting and management information systems and anticipate that we may implement new systems within the next twelve months. We could experience interruptions to our business while we transition to new systems. Our business will suffer if commercial users do not accept Internet solutions. Our business model depends on the adoption of Internet solutions by commercial users. Our business could suffer dramatically if Internet solutions are not accepted or not perceived to be effective. The Internet may not prove to be a viable commercial marketplace for a number of reasons, including: - inadequate development of the necessary infrastructure for communication speed, access and server reliability; - security and confidentiality concerns; - lack of development of complementary products, such as high-speed modems and high-speed communication lines; - implementation of competing technologies; - delays in the development or adoption of new standards and protocols required to handle increased levels of Internet activity; and - governmental regulation. We expect Internet use to grow in number of users and volume of traffic. The Internet infrastructure may be unable to support the demands placed on it by this continued growth. Growth in the demand for our applications and services depends on the adoption of Internet solutions by healthcare participants, which requires the acceptance of a new way of conducting business and exchanging information. The healthcare industry, in particular, relies on legacy systems that may be unable to benefit from our Internet-based platform. To maximize the benefits of our platform, healthcare participants must be willing to allow sensitive information to be stored in our databases. We can process transactions for healthcare participants that maintain information on their own proprietary databases. However, the benefits of our connectivity and sophisticated information management solution are limited under these circumstances. Customers using legacy and client-server systems may refuse to adopt new systems when they have made extensive investment in hardware, software and training for older systems. Performance or security problems with our systems could damage our business. Our customer satisfaction and our business could be harmed if we or our customers experience any system delays, failures or loss of data. We currently process substantially all our customer transactions and data at our facilities in Santa Clara, California and Atlanta, Georgia. Although we have safeguards for emergencies, we do not have backup facilities to process information if either of these facilities is not functioning. The occurrence of a major catastrophic event or other system failure at either the Santa Clara or the Atlanta facility could interrupt 13 14 data processing or result in the loss of stored data. In addition, we depend on the efficient operation of Internet connections from customers to our systems. These connections, in turn, depend on the efficient operation of Web browsers, Internet service providers and Internet backbone service providers, all of which have had periodic operational problems or experienced outages. A material security breach could damage our reputation or result in liability to us. We retain confidential customer and patient information in our processing centers. Therefore, it is critical that our facilities and infrastructure remain secure and that our facilities and infrastructure are perceived by the marketplace to be secure. Despite the implementation of security measures, our infrastructure may be vulnerable to physical break-ins, computer viruses, programming errors, attacks by third parties or similar disruptive problems. Technology may change faster than we can update our applications and services. Healthcare information exchange and transaction processing is a relatively new and evolving market. The pace of change in our markets is rapid and there are frequent new product introductions and evolving industry standards. We may be unsuccessful in responding to technological developments and changing customer needs. In addition, our applications and services offerings may become obsolete due to the adoption of new technologies or standards. Our platform infrastructure and its scalability are not proven. So far, we have processed a limited number and variety of transactions over our platform. Similarly, a limited number of healthcare participants use our platform. Our systems may not accommodate increased use while maintaining acceptable overall performance. We must continue to expand and adapt our network infrastructure to accommodate additional users, increased transaction volumes and changing customer requirements. This expansion and adaptation will be expensive and will divert our attention from other activities. Many of our service agreements contain performance standards. If we fail to meet these standards, our customers could terminate their agreements with us. The loss of any of our service agreements would directly and significantly impact our business. We may be unable to expand or adapt our network infrastructure to meet additional demand or our customers' changing needs on a timely basis and at a commercially reasonable cost, or at all. Our revenues are concentrated in a few customers. We expect that we will generate a significant portion of our revenue from a small number of customers for the next few years. If we do not generate as much revenue from these customers as we expect, or if we lose any of these customers, our revenue will be significantly reduced which would harm our business. For example, we receive a substantial majority of our revenue from four customers. UnitedHealth Group, SmithKline Labs, Brown & Toland and Beech Street each accounted for over 10% of our total revenue in the first quarter of 1999. As of April 28, 1999, UnitedHealth Group owned approximately 12.7% of our stock and SmithKline Labs owned approximately 8.8% of our stock. We face significant competition. The market for healthcare information services is intensely competitive, rapidly evolving and subject to rapid technological change. Many of our competitors have greater financial, technical, product development, marketing and other resources than we have. These organizations may be better known and have more customers than us. We may be unable to compete successfully against these organizations. Many of our competitors have announced or introduced Internet strategies that will compete with our applications and services. We have many competitors, including: - healthcare information software vendors, including HBO & Company and Shared Medical Systems Corporation; - healthcare electronic data interchange companies, including ENVOY Corporation and National Data Corporation; - large information technology consulting service providers, including Andersen Consulting, International Business Machines Corporation and Electronic Data Systems Corporation; and 14 15 - small regional organizations. In addition, we expect that major software information systems companies and others specializing in the healthcare industry will offer competitive applications or services. Some of our large customers may also compete with us. Changes in the healthcare industry could adversely affect our business. The healthcare industry is highly regulated and is subject to changing political, economic and regulatory influences. These factors affect the purchasing practices and operation of healthcare organizations. Changes in current healthcare financing and reimbursement systems could cause us to make unplanned modifications of applications or services, or result in delays or cancellations of orders or in the revocation of endorsement of our applications and services by healthcare participants. Federal and state legislatures have periodically considered programs to reform or amend the U.S. healthcare system at both the federal and state level. These programs may contain proposals to increase governmental involvement in healthcare, lower reimbursement rates or otherwise change the environment in which healthcare industry participants operate. Healthcare industry participants may respond by reducing their investments or postponing investment decisions, including investments in our applications and services. We do not know what effect any proposals would have on our business. Many healthcare providers are consolidating to create integrated healthcare delivery systems with greater market power. These providers may try to use their market power to negotiate price reductions for our applications and services. If we were forced to reduce our prices, our operating margins would decrease. As the healthcare industry consolidates, competition for customers will become more intense and the importance of acquiring each customer will become greater. Government regulation could adversely affect our business. Our business is subject to government regulation. Existing as well as new laws and regulations could adversely affect our business. Laws and regulations may be adopted with respect to the Internet or other on-line services covering issues such as: - user privacy; - pricing; - content; - copyrights; - distribution; and - characteristics and quality of products and services. Moreover, the applicability to the Internet of existing laws in various jurisdictions governing issues such as property ownership, sales and other taxes, libel and personal privacy is uncertain and may take years to resolve. Demand for our applications and services may be affected by additional regulation of the Internet. For example, until recently current Health Care Financing Administration guidelines prohibited transmission of Medicare eligibility information over the Internet. We are subject to extensive regulation relating to the confidentiality and release of patient records. Additional legislation governing the distribution of medical records has been proposed at both the state and federal level. It may be expensive to implement security or other measures designed to comply with any new legislation. Moreover, we may be restricted or prevented from delivering patient records electronically. Legislation currently being considered at the federal level could affect our business. For example, the Health Insurance Portability and Accountability Act of 1996 mandates the use of standard transactions, standard identifiers, security and other provisions by the year 2000. We are designing our platform and applications to comply with these proposed regulations; however, until these regulations become final, they could change, which could cause us to use additional resources and lead to delays in order to revise our platform and applications. In addition, our success depends on other healthcare participants complying with these regulations. Some computer applications and software are considered medical devices and are subject to regulation by the United States Food and Drug Administration, or the FDA. We do not believe that our current applications 15 16 or services are subject to FDA regulation. We may expand our application and service offerings into areas that subject us to FDA regulation. We have no experience in complying with FDA regulations. We believe that complying with FDA regulations would be time consuming, burdensome and expensive and could delay our introduction of new applications or services. We may face product-related liabilities. Although we and our customers test our applications, they may contain defects or result in system failures. In addition, our platform may experience problems in security, availability, scalability or other critical features. These defects or problems could result in the loss of or delay in generating revenue, loss of market share, failure to achieve market acceptance, diversion of development resources, injury to our reputation or increased insurance costs. Many of our strategic relationships and services agreements involve providing critical information technology services to our clients' businesses. Providing these services is complex because our clients have complex computing system environments. If we fail to meet our clients' expectations, our reputation could suffer and we could be liable for damages. In addition, patient care could suffer and we could be liable if our systems fail to deliver correct information in a timely manner. Our insurance may not protect us from this risk. Finally, we could become liable if confidential information is disclosed inappropriately. Our contracts limit our liability arising from our errors; however, these provisions may not be enforceable and may not protect us from liability. While we have general liability insurance that we believe is adequate, including coverage for errors and omissions, we may not be able to maintain this insurance on reasonable terms in the future. In addition, our insurance may not be sufficient to cover large claims and our insurer could disclaim coverage on claims. If we are liable for an uninsured or underinsured claim or if our premiums increase significantly, our financial condition could be materially harmed. Our proprietary technology may be subjected to infringement claims or may be infringed upon. Our intellectual property is important to our business. We could be subject to intellectual property infringement claims as the number of our competitors grows and the functionality of our applications overlaps with competitive offerings. These claims, even if not meritorious, could be expensive and divert our attention from operating our company. If we become liable to third parties for infringing their intellectual property rights, we would be required to pay a substantial damage award and to develop non-infringing technology, obtain a license or cease selling the applications that contain the infringing intellectual property. We may be unable to develop non-infringing technology or obtain a license on commercially reasonable terms, or at all. In addition, we may not be able to protect against misappropriation of our intellectual property. Third parties may infringe upon our intellectual property rights, we may not detect this unauthorized use and we may be unable to enforce our rights. Lengthy sales and implementation cycles for our solutions could adversely affect our revenue growth. A key element of our strategy is to market our solutions directly to large healthcare organizations. We are unable to control many of the factors that will influence our customers' buying decisions. We expect that the sales and implementation process will be lengthy and will involve a significant technical evaluation and commitment of capital and other resources by our customers. The sale and implementation of our solutions are subject to delays due to our customers' internal budgets and procedures for approving large capital expenditures and deploying new technologies within their networks. We will need to expend substantial resources to integrate our applications with the existing legacy and client-server architectures of large healthcare organizations. We have limited experience in integrating our applications with large, complex architectures, and we may experience delays in the integration process. These delays would, in turn, delay our ability to generate revenue from these applications and could adversely affect our results of operations. Our business will be adversely affected if we cannot attract and retain key personnel. 16 17 Our success will depend significantly on our senior management team and other key employees. We need to attract, integrate, motivate and retain additional highly skilled technical people. In particular, we need to attract experienced professionals capable of developing, selling and installing complex healthcare information systems. We face intense competition for these people. Our executive management team is critical to our success. We do not maintain key person life insurance for anyone. LIQUIDITY AND CAPITAL RESOURCES In February 1999, Healtheon completed the initial public offering of its common stock and realized net proceeds from the offering of approximately $41.4 million. Prior to the offering, Healtheon had funded its operations since inception primarily through the private placement of equity securities, through which we had raised net proceeds of $106.2 million through December 31, 1998. We have also financed our operations through equipment lease financing and bank borrowings. As of March 31, 1999, we had outstanding equipment lease liabilities of $5.5 million and borrowings against a line of credit of $1.1 million. As of March 31, 1999, we had approximately $63.2 million of cash, cash equivalents and short-term investments. Cash used in operating activities was $11.3 million in the first quarter of 1999 and $3.0 million in the first quarter of 1998. The cash used during these periods was primarily attributable to net losses. These losses were principally related to increased development and engineering expenses and sales, general and administrative expenses. Investments in property and equipment, excluding equipment acquired under capital leases or through the issuance of common stock, were $4.0 million in the first quarter of 1999 and $2.0 million in the first quarter of 1998. In the first quarter of 1999, Healtheon used $15.1 million of cash to purchase short-term investments and realized $7.8 million in cash from maturities of its short-term investments. In the first quarter of 1998, Healtheon used $3.1 million of cash to purchase short-term investments and realized $7.1 million in cash from maturities of its short-term investments. Cash provided by financing activities was $40.9 million in the first quarter of 1999, primarily from the net proceeds of our initial public offering of $41.4 million, as well as proceeds from exercises of employee stock options, offset slightly by payments totaling $0.9 million on capital lease obligations and line of credit borrowings. Financing activities used $0.1 million of cash in the first quarter of 1998, resulting primarily from payments of capital lease obligations. As of March 31, 1999, we did not have any material commitments for capital expenditures. Our principal commitments at March 31, 1999 consisted of obligations under operating leases and capital leases and our line of credit. We currently anticipate that our available cash resources and credit facilities will be sufficient to meet our presently anticipated working capital, capital expenditure and business expansion requirements for at least the next 12 months. However, we may need to raise additional funds within the next 12 months to support expansion, develop new or enhanced applications and services, respond to competitive pressures, acquire complementary businesses or technologies or take advantage of unanticipated opportunities. Our future liquidity and capital requirements will depend upon numerous factors, including the success of our existing and new application and service offerings and competing technological and market developments. We may be required to raise additional funds through public or private financing, strategic relationships or other arrangements. There can be no assurance that additional funding, if needed, will be available on terms acceptable to us, or at all. YEAR 2000 COMPLIANCE Many currently installed computer systems and software products are unable to distinguish between twentieth century dates and twenty-first century dates. As a result, many companies' software and computer systems may need to be upgraded or replaced to comply with these "Year 2000" requirements. Healtheon's business is dependent on the operation of numerous systems that could potentially be impacted by Year 2000 related problems. Those systems include, among others: hardware and software systems used by Healtheon to deliver services to its customers, including our proprietary software systems as well as hardware and software supplied by third parties; communications networks, such as the Internet and private intranets, which we depend on to provide electronic transactions to our customers; the internal systems of our customers and 17 18 suppliers; the hardware and software systems we use internally in the management of our business; and non-information technology systems and services we use in our business, such as telephone systems and building systems. Healtheon has reviewed the proprietary software systems we use to deliver services to our customers. Although we believe that our internally developed applications and systems are designed to be Year 2000 compliant, we utilize third-party equipment and software that may not be Year 2000 compliant. In January 1999, we acquired certain electronic laboratory connectivity devices from SmithKline Labs. SmithKline has warranted these services to be Year 2000 compliant. Also, two systems acquired by ActaMed, specifically SCAN and ProviderLink, which together accounted for approximately 42% of our total revenue in 1998, will require modifications to become Year 2000 compliant. We have released an updated version of SCAN which is Year 2000 compliant and we are in the process of deploying the updated version of SCAN to our customers. ProviderLink has two versions. The DOS version was made Year 2000 compliant and is currently being deployed to our DOS-based customers. The Internet version is being modified to be Year 2000 compliant and we expect to begin deployment over the Internet in mid-1999. We estimate the cost of these Year 2000 upgrades to be less than $1.0 million. In addition, our SCAN product is installed on approximately 4,650 Healtheon-owned workstations located in provider offices. Many of these workstations are not Year 2000 compliant and we must upgrade or replace them. We expect the costs of such upgrades or replacements to be less than $1.0 million. However, we could experience delays and cost overruns in the development of these upgrades, the upgrades could contain defects and we could experience difficulties in getting our installed base of physicians to implement these upgrades in a timely manner. If we experience these or other difficulties in developing and deploying our Year 2000 upgrades, our revenues from SCAN, ProviderLink and electronic laboratory delivery could be significantly reduced, which could have a material adverse effect on our business, financial condition and results of operations. Failure of third-party or of our equipment or software to operate properly with regard to the Year 2000 and thereafter could require us to incur unanticipated expenses to remedy any problems, which could have a material adverse effect on our business, financial condition and results of operations. In certain of our agreements, we warrant that our applications and services are Year 2000 compliant. Failure of our applications and services to be Year 2000 compliant could result in the termination of these agreements or in liability for damages, either of which could have a material adverse effect on our business, financial condition and results of operations. We do not believe that the expenditures to upgrade our internal systems and applications will have a material adverse effect on our business, financial condition and results of operations. Furthermore, the success of our efforts may depend on the success of other healthcare participants in dealing with their Year 2000 issues. Many of these organizations are not Year 2000 compliant, and the impact of widespread customer failure on Healtheon's systems is difficult to determine. Customer difficulties due to Year 2000 issues could interfere with healthcare transactions or information, which might expose us to significant potential liability. If client failures result in the failure of our systems, Healtheon's business, financial condition and results of operations would be materially adversely affected. Furthermore, the purchasing patterns of these customers or potential customers may be affected by Year 2000 issues as companies expend significant resources to become Year 2000 compliant. The costs of becoming Year 2000 compliant for current or potential customers may result in reduced funds being available to purchase and implement Healtheon's applications and services. Healtheon, with the assistance of an independent consulting firm specializing in Year 2000 issues, has completed a formal assessment of our Year 2000 exposure and is taking steps to address the identified points of exposure. We expect to complete our Year 2000 remediation efforts by mid-1999. We are in the process of developing a contingency plan for handling Year 2000 problems that are not detected and corrected prior to their occurrence. However, we are unable to make contingency plans if any significant number of the computers constituting the Internet fail to properly process dates for the year 2000 and there is a system-wide slowdown or breakdown. Any failure by us to address any unforeseen Year 2000 issue could adversely affect our business, financial condition and results of operations. Any interruption or significant degradation of Internet operations, whether due to Year 2000 problems or otherwise, could harm our business. 18 19 ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK INTEREST RATE SENSITIVITY The primary objective of Healtheon's investment activities is to preserve principal while at the same time maximizing the income we receive from our investments without significantly increasing risk. Some of the securities that we have invested in may be subject to market risk. This means that a change in prevailing interest rates may cause the principal amount of the investment to fluctuate. For example, if we hold a security that was issued with a fixed interest rate at the then-prevailing rate and the prevailing interest rate later rises, the principal amount of our investment will probably decline. To minimize this risk, we maintain our portfolio of cash equivalents and short-term investments in a variety of securities, including commercial paper, other non-government debt securities and money market funds. In general, money market funds are not subject to market risk because the interest paid on such funds fluctuates with the prevailing interest rate. In addition, we invest in relatively short-term securities. As of March 31, 1999, all of our investments mature in less than one year. The following table presents the amounts of our cash equivalents and short-term investments that are subject to market risk by range of expected maturity and weighted-average interest rates as of March 31, 1999. This table does not include money market funds because those funds are not subject to market risk.
MATURING IN --------------------------------------------------- THREE THREE MONTHS MONTHS TO FAIR OR LESS ONE YEAR TOTAL VALUE ------- -------- ------- ------- (DOLLARS IN THOUSANDS) Included in cash and cash equivalents $35,339 NA $35,339 $35,339 Weighted-average interest rate ..... 4.87% Included in short-term investments ... $15,011 $9,762 $24,773 $24,773 Weighted-average interest rates .... 4.97% 4.92%
EXCHANGE RATE SENSITIVITY Currently the majority of Healtheon's sales and expenses are denominated in U.S. dollars and as a result we have experienced no significant foreign exchange gains and losses to date. While we are conducting some transactions in foreign currencies during 1999, we do not anticipate that foreign exchange gains or losses will be significant. We have not engaged in foreign currency hedging activities to date. 19 20 PART II. OTHER INFORMATION ITEM 2. CHANGES IN SECURITIES AND USE OF PROCEEDS (d) Use of Proceeds. On February 11, 1999, Healtheon completed the initial public offering, or the offering, of its common stock. The managing underwriters in the offering were Morgan Stanley & Co. Incorporated, Goldman, Sachs & Co., Hambrecht & Quist LLC and Volpe Brown Whelan & Company. The shares of common stock sold in the offering were registered under the Securities Act of 1933, as amended, on a Registration Statement on Form S-1 (No. 333-70553). The Registration Statement was declared effective by the Securities and Exchange Commission on February 10, 1999. The offering commenced on February 11, 1999. The offering terminated on February 11, 1999 after we had sold all of the 5,750,000 shares of common stock registered under the Registration Statement (including 750,000 shares sold in connection with the exercise of the underwriters' over-allotment option). The initial public offering price was $8 per share for an aggregate initial public offering of $46,000,000. We paid a total of $3,220,000 in underwriting discounts and commissions. In addition, the following table itemizes the estimated expenses incurred in connection with the offering, other than underwriting discounts and commissions. None of the amounts shown was paid directly or indirectly to any director, officer, general partner of Healtheon or their associates, persons owning 10 percent or more of any class of equity securities of Healtheon or an affiliate of Healtheon. Securities and Exchange Commission registration fee........ $ 13,900 NASD filing fee............................................ 5,500 Nasdaq National Market listing fee......................... 94,000 Printing and engraving expenses............................ 260,000 Professional fees and expenses............................. 815,100 Blue Sky fees and expenses................................. 9,000 Transfer agent fees........................................ 17,500 Miscellaneous.............................................. 167,000 ---------- Total...................................................... $1,382,000 ==========
After deducting the underwriting discounts and commissions and the offering expenses, the net proceeds to Healtheon from the offering were approximately $41.4 million, which has been invested in short-term, interest-bearing, investment grade securities. ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K (a) Exhibits. The Exhibits listed in the accompanying Exhibit Index on page 6 are filed as part of this report. (b) No reports on Form 8-K were filed during the quarter ended March 31, 1999. The Company filed a report on Form 8-K on April 23, 1999 regarding the proposed acquisition of MedE America Corporation. 20 21 SIGNATURES In accordance with the requirements of the Securities Exchange Act, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. HEALTHEON CORPORATION Date: May 17, 1999 By: /s/ John L. Westermann III ---------------------------------------- John L. Westermann III Vice President, Chief Financial Officer, Secretary and Treasurer 21 22 EXHIBIT INDEX
EXHIBIT NO. DESCRIPTION - ----------- ----------- 10.01 Agreement and Plan of Reorganization dated April 20, 1999 by and among Healtheon Corporation, Merc Acquisition Corp. and MedE America Corporation. (Incorporated by reference from Healtheon's report on Form 8-K filed on April 23, 1999.) 27.01 Financial data schedule (EDGAR only)
22 dead monkeys EX-27.01 2 FINANCIAL DATA SCHEDULE
5 THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM HEALTHEON'S QUARTERLY REPORT ON FORM 10-Q FOR THE QUARTER ENDED MARCH 31, 1999 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS. 1,000 3-MOS 3-MOS DEC-31-1999 DEC-31-1998 JAN-01-1999 JAN-01-1998 MAR-31-1999 MAR-31-1998 38,389 15,358 24,786 1,324 10,424 4,785 0 0 0 0 75,160 22,545 28,920 12,223 11,510 4,442 121,055 51,075 22,171 14,531 0 0 0 54,638 0 43,756 7 1 95,724 (62,690) 121,055 51,075 0 0 17,555 9,754 0 0 16,860 7,948 19,822 10,834 0 0 139 116 (18,569) (9,676) 0 0 (18,569) (9,676) 0 0 0 0 0 0 (18,569) (9,676) (0.30) (1.19) (0.30) (1.19)
-----END PRIVACY-ENHANCED MESSAGE-----